Featured News

Data from the Nexvax2 study shows celiac patients exposed to gluten react within two hours and experience nausea and vomiting, not the classic lower digestive symptoms commonly associated with celiac disease.

Celiac disease is not considered to be an immunocompromised state in children, and is not known to be a risk factor for severe disease. Social distancing, washing hands with soap and water frequently and for at least 20 seconds, and avoiding touching of eyes, nose and mouth are recommended.

We are well on the way to assembling a grassroots advocacy team that can help make celiac disease a national priority in communities across the country

A recent review found that overall, the incidence of celiac disease has been rising since the second half of the 20th century into the 21st century in nearly every country where data on the disease are available.

The Celiac Disease Foundation National Patient Advocacy Summit in Washington, DC will train participants to advocate on celiac disease public policy priorities to Members of Congress.

More and more evidence is showing what many have long suspected: maintaining a truly gluten-free diet may not be possible.

On December 11, 2019, CEO Marilyn G. Geller was with Senator Blumenthal's legislative staff as Senator Richard Blumenthal (D-CT) introduced S.3021: Gluten in Medicine Disclosure Act of 2019 to the Senate. The Celiac Disease Foundation is proud to be a partner in this effort.

Researchers at the Mucosal Immunology and Biology Research Center (MIBRC) at Massachusetts General Hospital, led by Stefania Seger and CDF Medical Advisory Board member Alessio Fasano, have created 3-D, miniature models of the intestines in order to research celiac disease.

After decades of pleading with our federal government to take celiac disease as seriously as it does other diseases with comparable patient impact, yesterday, the U.S. House and Senate each passed, and President Trump has signed, the FY2020 Federal budget resolution.

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…